Aktien Sensor

Regeneron’s stock has taken a hit after analysts cut their target prices, but investors remain optimistic about the company’s potential, particularly its Dupixent treatment for COPD.

Regeneron Pharmaceuticals has made significant strides in key product developments, including FDA approval for Dupixent and consideration for expanding EYLEA HD treatment options.

Regeneron Pharmaceuticals is a biotech powerhouse on the rise, driven by its innovative approach, strong research pipeline, and commitment to emerging therapies.

Regeneron Pharmaceuticals faces a class action lawsuit alleging securities fraud, amidst a webcast and FDA decision on its linvoseltamab therapy, leaving investors on high alert.